Blood. 2016 Jan 7;127(1):3. doi: 10.1182/blood-2015-11-682948.
This paper, by one of the legends of hematology, William Dameshek, and his colleague Edward Miller, is from the inaugural issue of Blood. By studying bone marrow specimens from controls, patients with acute or chronic immune thrombocytopenia, or patients with other thrombocytopenic disorders, the authors concluded that, in idiopathic thrombocytopenic purpura (ITP), production of platelets from megakaryocytes is defective, even while marrow megakaryocytes are greatly increased in number. This defect resolved after splenectomy. The authors appropriately credit E. Frank with having proposed defective platelet production from megakaryocytes in ITP in 1915. The idea that platelet production was defective in ITP was superseded or ignored for decades, but it has now been validated by the therapeutic effectiveness of the thrombopoietin mimetics in ITP.
这篇论文由血液学传奇人物之一威廉·达梅谢克(William Dameshek)及其同事爱德华·米勒(Edward Miller)撰写,出自《Blood》的创刊号。通过研究来自对照组、急性或慢性免疫性血小板减少症患者或其他血小板减少症患者的骨髓标本,作者得出结论,在特发性血小板减少性紫癜(ITP)中,巨核细胞产生血小板存在缺陷,尽管骨髓巨核细胞数量大量增加。这一缺陷在脾切除术后得到解决。作者恰当地归功于 E. Frank 于 1915 年提出的 ITP 中巨核细胞产生血小板缺陷的观点。在 ITP 中血小板生成缺陷的观点被取代或忽视了几十年,但现在已被 ITP 中血小板生成素模拟物的治疗效果所验证。